New York-based Signal Capital Management, a hybrid hedge fund and private equity firm, has appointed Dr.
New York-based Signal Capital Management, a hybrid hedge fund and private equity firm, has appointed Dr. Roger von Hanwehr to its board of directors in the capacity of vice chairman.
Dr. von Hanwehr is the chief executive of Solus, a firm developing energy technologies, and is a co-founder of Arcxeon, a global technology, financial, and strategic consulting firm
He is an internationally recognised authority on biological, chemical and radiological defence; biomedicine; radiosurgery; renewable energy; space based technology; and the application of nanotechnology to these fields.
Dr. von Hanwehr teaches the Biodefense Colloquia in the biotechnology programme at Georgetown University, and is widely published.
He has been an advisor to the IST group at SDIO and BMDO and was a fellow at the Laboratory for Experimental Brain Research of the University of Lund, Sweden, where he specialized in tumour immunoncology, neuroimmunology and neurometabolism.
Dr. von Hanwehr will work with Signal to evaluate investment opportunities globally.
